Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Anti-cancer therapy: targeting the mevalonate pathway.

Swanson KM, Hohl RJ.

Curr Cancer Drug Targets. 2006 Feb;6(1):15-37. Review.

PMID:
16475974
2.
3.

Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.

Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.

J Med Chem. 1998 Nov 5;41(23):4492-501.

PMID:
9804689
4.
6.

Targeting the mevalonate pathway for improved anticancer therapy.

Fritz G.

Curr Cancer Drug Targets. 2009 Aug;9(5):626-38. Review.

PMID:
19508172
7.

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.

Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ.

Cancer Treat Rev. 2004 Nov;30(7):609-41. Review.

PMID:
15531395
8.

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.

J Bone Miner Res. 1998 Apr;13(4):581-9.

9.

Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).

Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y.

Br J Cancer. 1994 Jun;69(6):1015-20.

10.

Mevalonate-suppressive dietary isoprenoids for bone health.

Mo H, Yeganehjoo H, Shah A, Mo WK, Soelaiman IN, Shen CL.

J Nutr Biochem. 2012 Dec;23(12):1543-51. doi: 10.1016/j.jnutbio.2012.07.007. Review.

PMID:
22981371
11.

The mevalonate synthesis pathway as a therapeutic target in cancer.

Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD, Rosier RN.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S59-66. Review.

PMID:
14600593
12.

Novel aspects of mevalonate pathway inhibitors as antitumor agents.

Thurnher M, Nussbaumer O, Gruenbacher G.

Clin Cancer Res. 2012 Jul 1;18(13):3524-31. doi: 10.1158/1078-0432.CCR-12-0489. Review.

13.
14.

The intermediate enzymes of isoprenoid metabolism as anticancer targets.

Wiemer AJ, Hohl RJ, Wiemer DF.

Anticancer Agents Med Chem. 2009 Jun;9(5):526-42. Review.

PMID:
19519294
15.

Lipid posttranslational modifications. Farnesyl transferase inhibitors.

Basso AD, Kirschmeier P, Bishop WR.

J Lipid Res. 2006 Jan;47(1):15-31. Review.

16.

Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells.

Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ.

J Neurochem. 1998 Jun;70(6):2397-405.

17.

Ras as a target in cancer therapy.

Midgley RS, Kerr DJ.

Crit Rev Oncol Hematol. 2002 Nov;44(2):109-20. Review.

PMID:
12413630
18.

Potential antitumor effects of statins (Review).

Jakobisiak M, Golab J.

Int J Oncol. 2003 Oct;23(4):1055-69. Review.

PMID:
12963986
19.

Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis.

Singh RP, Kumar R, Kapur N.

J Environ Pathol Toxicol Oncol. 2003;22(2):75-92. Review.

PMID:
14533871
20.

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Nat Rev Drug Discov. 2007 Jul;6(7):541-55. Review.

PMID:
17585331

Supplemental Content

Support Center